Both directions are real, and they are not the same size.

The strongest, longest-lasting benefit is a meaningful reduction in ovarian cancer risk that grows with years of use and persists for decades after stopping; long-term data also link pill use to reduced risk of several other cancers. On the other side, current and recent hormonal contraception use is linked to a modest increase in breast cancer risk, which is real but small in absolute terms, roughly one extra breast cancer per several thousand women using it for a year. One honest gap: there is no dedicated breast cancer research specifically in women aged 40 to 50 using combined pills, so that particular age-and-risk combination has not been directly studied.

What to know about this answer

The genuine tension here is not between two camps disputing the data, but between reporting the breast cancer finding as a relative-risk number versus an absolute-risk number, since the two create very different impressions of the same study.

What the research shows, and which source each finding rests on

A large collaborative reanalysis of 45 studies covering over 23,000 women with ovarian cancer found each 5 years of pill use was associated with about a 20% reduction in ovarian cancer risk, an effect that persisted more than 30 years after stopping.

A[1]

A long-term UK cohort followed for up to 44 years found ever-use of the pill associated with reduced risk of colorectal, endometrial, ovarian, and blood/lymph system cancers, with any excess breast and cervical cancer risk disappearing within about 5 years of stopping, and an overall neutral lifetime cancer balance.

D[2]

A large Danish cohort of 1.8 million women found current and recent hormonal contraception users had a 20% relative increase in breast cancer risk compared with never-users, rising with duration of use; the same study found the absolute increase was about 13 extra cases per 100,000 person-years, roughly 1 extra breast cancer for every 7,690 women using hormonal contraception for 1 year.

C[3]

Guidelines note there is a dearth of evidence regarding combined hormonal contraception and breast cancer risk that relates specifically to women over 40, so this is not a distinctly studied population for that outcome.

A[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the relative risk increase is the headline that should be communicated

how the breast cancer finding is most often summarized publicly

A 20% relative increase in breast cancer risk, rising further with duration of use, is a real, statistically robust finding from a very large cohort and deserves to be taken seriously in any risk discussion.

C[3]

the relative risk must be paired with the absolute risk or it distorts the picture

the study's own authors, whose absolute-risk figure is presented alongside the relative risk

The same study's authors specifically reported the absolute increase, about 1 extra breast cancer per 7,690 women using hormonal contraception for a year, and presenting the relative risk alone without this figure is flagged as a textbook example of relative-risk distortion.

C[3]

What would settle it: This is less an open scientific question than a communication standard; consistently pairing relative and absolute risk figures resolves it, and dedicated research in the 40-50 age group specifically would close the remaining evidence gap for that population.

What is really going on here

  1. Presenting the 20% relative breast cancer risk increase without its absolute companion figure (about 1 in 7,690 per year of use) is specifically flagged as a distortion to avoid.
  2. No study has looked at combined pill breast cancer risk as a distinct question in women aged 40-50 specifically; the existing data come from broader age ranges.

Questions for your doctor

  1. Given my family history, how should I weigh the ovarian cancer protection against the breast cancer signal?
  2. Does my personal risk profile change this calculation in either direction?
  3. How many more years would you recommend I continue, if cancer risk is my main consideration?
  4. Are there screening steps we should have in place given my pill use?

Questions with no answer yet

Is the modest breast cancer risk increase from hormonal contraception different, in either direction, specifically in women aged 40-50, or does it behave the same as in the broader age ranges that have actually been studied?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Guidelines note there is a dearth of evidence regarding combined hormonal contraception and breast cancer risk that relates specifically to women over 40; the existing large studies span broader age ranges without isolating this specific decade.

What would test it: A dedicated analysis of breast cancer risk in hormonal contraception users restricted specifically to the 40-50 age band, ideally from an existing large cohort with enough statistical power to isolate that group.

Does the ovarian cancer protection from pill use persist at the same magnitude in women who start or continue the pill specifically during perimenopause, or was that protection measured mainly in women who used the pill earlier in reproductive life?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The collaborative reanalysis establishing ovarian cancer risk reduction pooled data across a wide range of ages and use patterns; the source material does not identify a study isolating whether perimenopausal-specific use produces the same protective magnitude as use begun earlier in reproductive life.

What would test it: An age-stratified analysis of the existing ovarian cancer cohort data, isolating protection specifically attributable to perimenopausal-era pill use.

Sources

  1. 1.Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.Collaborative Group on Epidemiological Studies of Ovarian Cancer; Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371(9609):303-14. · Systematic review or guideline
  2. 2.Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017;216(6):580.e1-580.e9. · Comparative or small study
  3. 3.Contemporary Hormonal Contraception and the Risk of Breast Cancer.Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017;377(23):2228-39. · Observational study
  4. 4.FSRH. Contraception for Women Aged Over 40 Years. Guideline, August 2017 (amended September 2019, further amended July 2023).Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides